Stockpolly
Search
SPRB · NASDAQ · Biotechnology

Spruce Biosciences (SPRB)

Develops an enzyme therapy for Sanfilippo syndrome and a preclinical CAH antibody.

$59.00
Pre-market−0.68 (−1.14%)
At close$59.68(+7.34%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue332211000000
Cost of revenue000000000000
Gross profit332211000000
1714151210251438111217
Research & development131110872111054812
334433433744
General & administrative304433433744
Other expenses000000000000
Operating income−14−11−13−10−9−24−14−3−8−11−12−17
111111010−400
Interest income111111010000
Interest expense000000000011
Other non-operating income−1−1−1−1−1−10−1040−1
Income before tax−12−10−12−9−9−24−14−2−8−15−12−16
Net income from continuing operations−12−10−12−9−9−24−14−2−8−15−12−16
Net income−12−10−12−9−9−24−14−2−8−15−12−16
EPS, basic−$22.50−$18.00−$21.00−$16.50−$16.50−$43.50−$24.00−$3.41−$14.58−$10.67−$8.94−$6.68
EPS, diluted−$22.50−$18.00−$21.00−$16.50−$16.50−$43.50−$24.00−$3.41−$14.58−$10.67−$8.94−$6.68
Weighted average shares, basic1———11111112
Weighted average shares, diluted1———11111112
EBITDA−12−10−12−9−9−23−14−2−8−15−11−15
Depreciation & amortization000000000001
EBIT−12−10−12−9−9−24−14−2−8−15−12−15